Method 1668C: Chlorinated Biphenyl Congeners in Water, Soil, Sediment, Biosolids, and Tissue by HRGC/HRMS
Total Page：16
File Type：pdf, Size：1020Kb
Method 1668C Chlorinated Biphenyl Congeners in Water, Soil, Sediment, Biosolids, and Tissue by HRGC/HRMS April 2010 U.S. Environmental Protection Agency Office of Water Office of Science and Technology Engineering and Analysis Division (4303T) 1200 Pennsylvania Avenue, NW Washington, DC 20460 EPA-820-R-10-005 EPA Method 1668C ii April 2010 Method 1668C Chlorinated Biphenyl Congeners in Water, Soil, Sediment, Biosolids, and Tissue by HRGC/HRMS April 2010 The Office of Science and Technology (OST) in EPA’s Office of Water developed Method 1668C (Method 1668C; the “Method”) for use in Clean Water Act (CWA) programs. EPA is publishing this Method for users who wish to measure PCBs as congeners now, and in 2010, EPA expects to publish a proposal in the Federal Register for public comment to add this Method to other CWA Methods published at 40 CFR Part 136. This Method determines chlorinated biphenyl congeners in environmental samples by isotope dilution and internal standard high-resolution gas chromatography/high-resolution mass spectrometry, HRGC/HRMS. EPA developed this Method for use in wastewater, surface water, soil, sediment, biosolids and tissue matrices. Other applications and matrices may be possible, which may or may not require modifications of sample preparation, chromatography, etc. EPA used the results of an interlaboratory validation study of Method 1668A, a peer review of that study, user suggestions and additional interlaboratory data to write this version, 1668C, of Method 1668. Method 1668C, the validation study report, Method1668A Interlaboratory Validation Study Report (EPA 821-08-021), and the addendum describing the revised QC acceptance criteria, Method 1668A Interlab Study Report Addendum, are available at EPA’s CWA methods website at www.epa.gov/waterscience/methods. This “C” version of Method 1668 revises the quality control (QC) acceptance criteria in EPA Method 1668B to allow the upper recovery limit for some congeners to be above 100 percent, to revise the estimated method detection limits (EMDLs) and estimated minimum levels of quantitation (EMLs) to MDLs and MLs, and to makes other changes summarized below. The QC acceptance criteria developed in the interlaboratory method validation study of 1668A, and published in version B of the Method, did not allow the upper recovery limit for some congeners to be above 100 percent. The criteria have been revised based on data from the interlaboratory study and data from two laboratories with extensive experience in use of Method 1668A. TestAmerica, Knoxville, Tennessee and AXYS Analytical Services, Ltd., Sidney, British Columbia, Canada provided this new data. These two laboratories and Battelle- Columbus provided MDLs for the congeners and congener groups, which EPA pooled and used to replace the EMDLs and EMLs in Table 2 of Method 1668B with the MDLs and MLs in Method 1668C. The detection limits and quantitation levels in this Method are usually dependent on the level of inter ferences and laboratory background levels rather than instrumental limitations. The method detection limits (MDLs) and minimum levels of quantitation (MLs) in Table 2 are concentrations at which a congener can be measured with no interferences present. In water, MDLs range from approximately 7 to 30 parts per quadrillion (picograms per liter, pg/L). Interface, Inc. and CSC prepared this Method under EPA Contract EP-C-06-085. AXYS Analytical provided the single-lab data in Method 1668A that was later replaced by multi-lab data from laboratories that participated in EPA's inter-laboratory validation of 1668A (six labs for water and tissue, four for biosolids). Summary of changes between EPA Method 1668B (January 2009) and 1668C (April 2010) • Additional information on the concentration of extracts has been included in Section 4.2. • The following note has been added to Section 10.1, “RTs, RRTs, and RRT limits may differ slightly from those in Table 2.” This statement has also been added to the footnotes to Table 2. EPA Method 1668C iii April 2010 • The note in Section 10.2.1 has been modified to inform the analyst that careful selection of the grade and purity of PFK may help minimize interferences with the dichlorobiphenyl secondary quantitation ion. • The diluted combined 209 congener solution is now used for calibration verification, in place of the VER-3 solution. This allows all verification tests to be performed with a single solution. • Section 17.2.1 has been changed to clarify that concentrations of native compounds other than those in the native toxics/LOC standard, in the labeled cleanup standard, and in the labeled injection internal standard (except for labeled CB 178) should be determined using the response factors from Section 10.5 or Section 15.4.2.3. • Section 17.6.5 has been added to provide information on the use of optional data qualifier flags for reporting coeluting congeners. • Based on data from the interlab validation study and data from two laboratories, the QC acceptance criteria in Table 6 have been revised to be consistent among tests for calibration verification (VER), initial precision and recovery (IPR), on-going precision and recovery (OPR), and labeled compound recovery from samples. • Reference 22 has been added to cite the Addendum to the interlaboratory validation study report. • Sections 1.3, 4.1, 4.6, 9.1.2.1, 9.5.2, 10.3.3, 17.6.1.4.1, 17.6.1.4.2, 17.6.1.4.3, and Table 2 been revised to change estimated method detection limits (EMDLs) and estimated minimum levels of quantitation (EMLs) to MDLs and MLs. • Reference 23 has been added to cite the MDL data from AXYS, TestAmerica-Knoxville, and Battelle-Columbus, and to explain how these data were processed to produce the pooled MDLs in Table 2. • A sentence was added to Section 11.4.2.1 to require weighing the sample bottle after emptying, and to determine the volume using the density of water. • ML definition revised to cite the ML procedure. • A note was added to Section 10.3.3 to state that MDLs and MLs lower than those in Table 2 may be established per Section 17.6.1.4.1. • Section 17.6.1.4.1 expanded to state how MDLs and MLs lower than those in Table 2 may be established. • A footnote was added to Table 2 to cite Reference 23. Summary of changes between EPA Method 1668A (8-20-03) and 1668B (January 2009) (excluding typographical and grammatical error corrections, and section insertions or deletions necessitated by the following changes). • Based on the interlaboratory validation study, single-laboratory QC acceptance criteria are replaced with interlaboratory criteria (Table 6). A new footnote 1 to Table 6 references the EPA interlaboratory study report, and the other footnote numbers are incremented. EPA Method 1668C iv April 2010 • Section 1.5, the performance-based discussion, describes additional flexibility to modify CWA Methods that is allowed by 40 CFR Part 136.6. • Section 2.5.2 now indicates that internal standards are the labeled congeners spiked into the sample. • Section 2.5.3 now indicates that injection internal standards are labeled compounds spiked into the extract. • Section 5.4 is an added section on biohazards. • Section 7.8 notes that Method 1668A part numbers are valid for Method 1668B. • Section 8.1 allows use of alternate sample collection techniques, if documented. • Section 8.2 adds that one liter, or a larger or smaller volume of sample, may be collected. • Section 12.3 adds a note to indicate that SDS extraction may cause loss of some mono- through tri chloro congeners. • Section 12.5.6 states that a macro concentration device is to be used to concentrate extracts, and deletes the requirement for collection of the extract in a round-bottom flask because any macro concentration device may be used. • Section 16.2 requires an expert spectrometrist to determine analyte presence when an interference precludes meeting the signal-to-noise requirement for dichloro-CB congeners. • Section 21 cites the validation studies, and that performance data are in the interlaboratory validation study report. • Reference 1 was updated to the 2006 World Health Organization paper on toxicity equivalency factors. • References 4 and 17 add titles to the papers in these references. • Reference 21 cites the Method 1668A Interlaboratory Validation Study Report. • Tables 2 and A-1 revised the elution order for congeners 107-109. • Table 4 defines the solutions containing congeners 107, 108, and 109. • Table 6 contains revised QC acceptance criteria for performance tests, and footnote 1 to Table 6 references the Method 1668A Interlaboratory Validation Study Report. • Table 7 adds footnote 2 to require meeting the 10:1 signal-to-noise specification at the CS-2 calibration level. EPA Method 1668C v April 2010 Summary of corrections and changes to EPA Method 1668A as of August 20, 2003 (excluding typographical and grammatical error corrections, and section insertions or deletions necessitated by the following changes). • Throughout: All references to IUPAC have been deleted. We have been informed that IUPAC does not assign congener numbers. Therefore, all references to congeners by number are to “congener number.” The congener naming system given by Guitart, et al. (Guitart R., Puig P., Gomez-Catalan J., Chemosphere 27 1451-1459, 1993) has been used in EPA Method 1668A since its inception and continues in this version. • Sections 2.1.3, 12.4.2., 12.4.3, 12.4.5, and 12.4.9: Hexane has be deleted from the extraction solvent for fish and other tissue to preclude loss of the more volatile CBs. • Section 7.7: A note has been added to reference the two known suppliers of labeled compounds. • Section 7.15: A statement has been added to include certified reference materials (CRMs) from the National Resource Council of Canada.